Kald Abdallah
Research Subjects
Kald Abdallah has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Brenda Hernandez
Bristol Myers Squibb
1 shared publication- Derek C. Angus
University of Pittsburgh, Pittsburgh, PA
1 shared publication - Donna R. Rivera
Oncology Center of Excellence, US Food and Drug Administration, Silver Spring, MD
1 shared publication - Douglas R. Lowy
Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
1 shared publication - Elizabeth Garrett-Mayer
American Society of Clinical Oncology, Alexandria, VA
1 shared publication Iryna Shnitsar
Bristol Myers Squibb
1 shared publication
Latest Publications
- Open Access
- 3 April 2023
- Published by Taylor & Francis in Journal of Workplace Behavioral Health
- Vol. 38 (2) , 165-187
Personality diversity in the workplace: A systematic literature review on introversion
Up to half of the population have introverted personalities. Workplace diversity can lead to increased productivity, creativity and problem-solving. Understanding introversion in relation to workplace performance and creativity and how to encourage inclusion of introverts would benefit employers and employees. We describe the evidence defining and evaluating introversion, prevalence of introversion across groups, and strategies for promoting workplace inclusion of introverts. We searched MEDLINE®, Embase, and PsycINFO up to February 11, 2021. Of 2,724 records, 21 studies were included. Introversion definitions were generally negative and dated. Robust prevalence data were unavailable, and no studies aimed to test strategies for promoting workplace inclusion of introversion. Nevertheless, literature suggests that employees who identify with modern definitions of introversion may benefit from individualized workplace strategies such as flexible working environments, work/home-life boundaries, varied team composition, provision of social support, and relaxation training. Further empirical studies in the industrial setting with robust designs using modernized personality definitions are warranted to support the development of effective strategies to increase inclusion of different personalities in the workplace.
- 3 April 2023
- Published by Taylor & Francis in Journal of Workplace Behavioral Health
- Vol. 38 (2) , 165-187
Open AccessPersonality diversity in the workplace: A systematic literature review on introversion
Up to half of the population have introverted personalities. Workplace diversity can lead to increased productivity, creativity and problem-solving. Understanding introversion in relation to workplace performance and creativity and how to encourage inclusion of introverts would benefit employers and employees. We describe the evidence defining and evaluating introversion, prevalence of introversion across groups, and strategies for promoting workplace inclusion of introverts. We searched MEDLINE®, Embase, and PsycINFO up to February 11, 2021. Of 2,724 records, 21 studies were included. Introversion definitions were generally negative and dated. Robust prevalence data were unavailable, and no studies aimed to test strategies for promoting workplace inclusion of introversion. Nevertheless, literature suggests that employees who identify with modern definitions of introversion may benefit from individualized workplace strategies such as flexible working environments, work/home-life boundaries, varied team composition, provision of social support, and relaxation training. Further empirical studies in the industrial setting with robust designs using modernized personality definitions are warranted to support the development of effective strategies to increase inclusion of different personalities in the workplace.
- 28 March 2022
- Published by Wolters Kluwer Health in The Cancer Journal
- Vol. 28 (2) , 151-156
Clinical Evidence Generation During a Pandemic
Because of significant adaptations forced by the COVID-19 pandemic, resultant changes within health care delivery and clinical research introduced the potential for evaluation of novel evidence generation approaches in oncology. On July 26 and 27, 2021, the National Academies of Science, Engineering, and Medicine, National Cancer Policy Forum hosted a virtual workshop entitled “Cancer Care and Cancer Research in the Context of the COVID-19 Pandemic: A Workshop on Lessons Learned.” This workshop examined changes in cancer care and cancer research that occurred in response to the COVID-19 pandemic and considered lessons learned from that experience. The goal was to identify what changes could improve the delivery of high-quality cancer care and the conduct of cancer clinical trials in the postpandemic era, with an emphasis on health equity. How can we sustain the valuable lessons learned that might accelerate progress and enhance clinical evidence generation for patients and clinicians? In this overview, we discuss ways in which the COVID-19 experience has catalyzed research efficiencies as well as fostered a broader array of trial design and research methods that may facilitate improved cancer drug development during the pandemic and beyond.
- 28 March 2022
- Published by Wolters Kluwer Health in The Cancer Journal
- Vol. 28 (2) , 151-156
Clinical Evidence Generation During a Pandemic
Because of significant adaptations forced by the COVID-19 pandemic, resultant changes within health care delivery and clinical research introduced the potential for evaluation of novel evidence generation approaches in oncology. On July 26 and 27, 2021, the National Academies of Science, Engineering, and Medicine, National Cancer Policy Forum hosted a virtual workshop entitled “Cancer Care and Cancer Research in the Context of the COVID-19 Pandemic: A Workshop on Lessons Learned.” This workshop examined changes in cancer care and cancer research that occurred in response to the COVID-19 pandemic and considered lessons learned from that experience. The goal was to identify what changes could improve the delivery of high-quality cancer care and the conduct of cancer clinical trials in the postpandemic era, with an emphasis on health equity. How can we sustain the valuable lessons learned that might accelerate progress and enhance clinical evidence generation for patients and clinicians? In this overview, we discuss ways in which the COVID-19 experience has catalyzed research efficiencies as well as fostered a broader array of trial design and research methods that may facilitate improved cancer drug development during the pandemic and beyond.